A proof-of-concept study of CUSP06
Latest Information Update: 08 Jan 2024
At a glance
- Drugs CUSP-06 (Primary)
- Indications Cholangiocarcinoma; Ovarian cancer; Renal cancer
- Focus Proof of concept; Therapeutic Use
Most Recent Events
- 08 Jan 2024 New trial record
- 04 Jan 2024 According to OnCusp Therapeutics media release, company Raised Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients to clinical proof-of-concept